Coagulation profile and platelet function in patients with extrahepatic portal vein obstruction and non-cirrhotic portal fibrosis

[Guest guest]

1: J Gastroenterol Hepatol 2001 Jun;16(6):641-6

Coagulation profile and platelet function in patients with extrahepatic

portal vein obstruction and non-cirrhotic portal fibrosis.

Bajaj JS, Bhattacharjee J, Sarin SK.

Departments of; Gastroenterology and; Biochemistry, Govind Ballabh Pant

Hospital, New Delhi, India.

BACKGROUND AND AIMS: Coagulation disorders commonly develop in patients with

cirrhosis of the liver. They have also been reported in patients with

non-cirrhotic portal fibrosis (NCPF) and extra-hepatic portal venous

obstruction (EHPVO); the two conditions with portal hypertension and

near-normal liver functions. The spectrum and prevalence of coagulation

abnormalities and their association with the pathogenesis of these diseases

and with hypersplenism was prospectively studied. METHODS: Eighteen EHPVO

patients that included an equal number of NCPF patients and 20 healthy

controls were prospectively studied. The coagulation parameters assessed

included: international normalized ratio, partial thromboplastin time, and

fibrinogen and fibrinogen degradation products. Platelet aggregation and

malondialdehyde levels were measured. RESULTS: Both EHPVO (83%) and NCPF

(78%) patients had a significantly prolonged international normalized ratio

and a decrease in fibrinogen and platelet aggregation. The EHPVO patients

had a significant prolongation in partial thromboplastin time (67%

patients), with increased levels of fibrinogen degradation product levels

occurring in all patients; these were normal in NCPF patients. Platelet

malondialdehyde levels were normal in both groups. Hypersplenism was present

in four EHPVO and seven NCPF patients. It did not significantly influence

the coagulation profile in either NCPF or EHPVO patients. CONCLUSIONS:

Coagulation anomalies are common and significant in both NCPF and EHPVO

patients, suggestive of a mild disseminated intravascular coagulation

disorder. These imbalances could be caused by chronic subclinical

endotoxemia and cytokine activation after the initial portal thromboembolic

event. The persistence of these abnormalities in adolescent patients

indicates an ongoing coagulation derangement.

PMID: 11422617 [PubMed - in process]

______________________

[Guest guest]

1: J Gastroenterol Hepatol 2001 Jun;16(6):641-6

Coagulation profile and platelet function in patients with extrahepatic

portal vein obstruction and non-cirrhotic portal fibrosis.

Bajaj JS, Bhattacharjee J, Sarin SK.

Departments of; Gastroenterology and; Biochemistry, Govind Ballabh Pant

Hospital, New Delhi, India.

BACKGROUND AND AIMS: Coagulation disorders commonly develop in patients with

cirrhosis of the liver. They have also been reported in patients with

non-cirrhotic portal fibrosis (NCPF) and extra-hepatic portal venous

obstruction (EHPVO); the two conditions with portal hypertension and

near-normal liver functions. The spectrum and prevalence of coagulation

abnormalities and their association with the pathogenesis of these diseases

and with hypersplenism was prospectively studied. METHODS: Eighteen EHPVO

patients that included an equal number of NCPF patients and 20 healthy

controls were prospectively studied. The coagulation parameters assessed

included: international normalized ratio, partial thromboplastin time, and

fibrinogen and fibrinogen degradation products. Platelet aggregation and

malondialdehyde levels were measured. RESULTS: Both EHPVO (83%) and NCPF

(78%) patients had a significantly prolonged international normalized ratio

and a decrease in fibrinogen and platelet aggregation. The EHPVO patients

had a significant prolongation in partial thromboplastin time (67%

patients), with increased levels of fibrinogen degradation product levels

occurring in all patients; these were normal in NCPF patients. Platelet

malondialdehyde levels were normal in both groups. Hypersplenism was present

in four EHPVO and seven NCPF patients. It did not significantly influence

the coagulation profile in either NCPF or EHPVO patients. CONCLUSIONS:

Coagulation anomalies are common and significant in both NCPF and EHPVO

patients, suggestive of a mild disseminated intravascular coagulation

disorder. These imbalances could be caused by chronic subclinical

endotoxemia and cytokine activation after the initial portal thromboembolic

event. The persistence of these abnormalities in adolescent patients

indicates an ongoing coagulation derangement.

PMID: 11422617 [PubMed - in process]

______________________

[Guest guest]

1: J Gastroenterol Hepatol 2001 Jun;16(6):641-6

Coagulation profile and platelet function in patients with extrahepatic

portal vein obstruction and non-cirrhotic portal fibrosis.

Bajaj JS, Bhattacharjee J, Sarin SK.

Departments of; Gastroenterology and; Biochemistry, Govind Ballabh Pant

Hospital, New Delhi, India.

BACKGROUND AND AIMS: Coagulation disorders commonly develop in patients with

cirrhosis of the liver. They have also been reported in patients with

non-cirrhotic portal fibrosis (NCPF) and extra-hepatic portal venous

obstruction (EHPVO); the two conditions with portal hypertension and

near-normal liver functions. The spectrum and prevalence of coagulation

abnormalities and their association with the pathogenesis of these diseases

and with hypersplenism was prospectively studied. METHODS: Eighteen EHPVO

patients that included an equal number of NCPF patients and 20 healthy

controls were prospectively studied. The coagulation parameters assessed

included: international normalized ratio, partial thromboplastin time, and

fibrinogen and fibrinogen degradation products. Platelet aggregation and

malondialdehyde levels were measured. RESULTS: Both EHPVO (83%) and NCPF

(78%) patients had a significantly prolonged international normalized ratio

and a decrease in fibrinogen and platelet aggregation. The EHPVO patients

had a significant prolongation in partial thromboplastin time (67%

patients), with increased levels of fibrinogen degradation product levels

occurring in all patients; these were normal in NCPF patients. Platelet

malondialdehyde levels were normal in both groups. Hypersplenism was present

in four EHPVO and seven NCPF patients. It did not significantly influence

the coagulation profile in either NCPF or EHPVO patients. CONCLUSIONS:

Coagulation anomalies are common and significant in both NCPF and EHPVO

patients, suggestive of a mild disseminated intravascular coagulation

disorder. These imbalances could be caused by chronic subclinical

endotoxemia and cytokine activation after the initial portal thromboembolic

event. The persistence of these abnormalities in adolescent patients

indicates an ongoing coagulation derangement.

PMID: 11422617 [PubMed - in process]

______________________

[Guest guest]

1: J Gastroenterol Hepatol 2001 Jun;16(6):641-6

Coagulation profile and platelet function in patients with extrahepatic

portal vein obstruction and non-cirrhotic portal fibrosis.

Bajaj JS, Bhattacharjee J, Sarin SK.

Departments of; Gastroenterology and; Biochemistry, Govind Ballabh Pant

Hospital, New Delhi, India.

BACKGROUND AND AIMS: Coagulation disorders commonly develop in patients with

cirrhosis of the liver. They have also been reported in patients with

non-cirrhotic portal fibrosis (NCPF) and extra-hepatic portal venous

obstruction (EHPVO); the two conditions with portal hypertension and

near-normal liver functions. The spectrum and prevalence of coagulation

abnormalities and their association with the pathogenesis of these diseases

and with hypersplenism was prospectively studied. METHODS: Eighteen EHPVO

patients that included an equal number of NCPF patients and 20 healthy

controls were prospectively studied. The coagulation parameters assessed

included: international normalized ratio, partial thromboplastin time, and

fibrinogen and fibrinogen degradation products. Platelet aggregation and

malondialdehyde levels were measured. RESULTS: Both EHPVO (83%) and NCPF

(78%) patients had a significantly prolonged international normalized ratio

and a decrease in fibrinogen and platelet aggregation. The EHPVO patients

had a significant prolongation in partial thromboplastin time (67%

patients), with increased levels of fibrinogen degradation product levels

occurring in all patients; these were normal in NCPF patients. Platelet

malondialdehyde levels were normal in both groups. Hypersplenism was present

in four EHPVO and seven NCPF patients. It did not significantly influence

the coagulation profile in either NCPF or EHPVO patients. CONCLUSIONS:

Coagulation anomalies are common and significant in both NCPF and EHPVO

patients, suggestive of a mild disseminated intravascular coagulation

disorder. These imbalances could be caused by chronic subclinical

endotoxemia and cytokine activation after the initial portal thromboembolic

event. The persistence of these abnormalities in adolescent patients

indicates an ongoing coagulation derangement.

PMID: 11422617 [PubMed - in process]

______________________